Company: BIVIW
Filing Date: 2025-02-11
Form Type: 10-Q
Source: 0001520138-25-000056
Chunk: 7

Company: BIOVIE INC.
Filing Date: 2025-02-11
Form: 10-Q
Item: Part I, Item 2
Chunk 7
---
.7 million and $15.3 million for the six months ended December 31, 2024 and 2023, respectively. The $8.7 million net decline was primarily
attributed to the completion of the clinical studies in the prior fiscal year and comprised of a net decrease in direct study costs of
approximately $4.6 million, and decreases in related expenses such as the clinical team payroll of $1.4 million, reflecting the reduction
in force in December 2023, and consultants expenses of $1.9 million, reflecting a declining use of consultants and a reduction in the
use of regulatory and other consultants totaling approximately $440,000 as the clinical studies completed in the prior fiscal year, a
decrease in Chemistry, Manufacturing and Controls (“CMC”) and new drug discovery totaling approximately $179,000, and a decrease
in travel & conferences of approximately $93,000 and publications of approximately $93,000.

 25 

The decrease in clinical studies of approximately
$4.6 million represented the net decrease in clinical trial studies expense due the completion of the clinical trials in the prior fiscal
year offset by the planning and development of the two new clinical studies PD and LC. The table below summarizes the expense amounts
for the six months ended December 31, 2024 and 2023 by study:

    Six Months Ended  
    Six Months Ended  
    Increase 

    December 31, 2024  
    December 31, 2023  
    (Decrease) 

    Current Studies 

    Sunrise PD Phase 2 
    $ 1,677,534  
    $ 20,000  
    $ 1,657,534 
  
    Long Covid Program, net of $325,000 reimbursement 
     2,401,028  
     -  
     2,401,028 
  
    Investigator-Initiated studies 
     12,738  
     -  
     12,738 

    $ 4,091,300  
    $ 20,000  
    $ 4,071,300 

    Completed Studies 

    Ascites BIV201 Phase 2b 
    $ (11,117) 
    $ 517,006  
    $ (528,123)
  
    AD mild to moderate pivotal Phase 3 
     44,124